PEN Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of 12.93% compared to Penumbra, Inc.'s net margin of 31.72%. Penumbra, Inc.'s return on equity of 13.4% beat Eli Lilly & Co.'s return on equity of 106.26%.

Penumbra, Inc. has a consensus price target of $306.79, signalling upside risk potential of 7.38%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,045.59 which suggests that it could grow by 1.16%. Given that Penumbra, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Penumbra, Inc. is more attractive than Eli Lilly & Co..

Penumbra, Inc. has a beta of 0.663, which suggesting that the stock is 33.676% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Penumbra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Penumbra, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Penumbra, Inc. quarterly revenues are $354.7M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Penumbra, Inc.'s net income of $45.9M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Penumbra, Inc.'s price-to-earnings ratio is 68.28x while Eli Lilly & Co.'s PE ratio is 51.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra, Inc. is 8.39x versus 15.86x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems, Inc. has a net margin of 12.93% compared to Penumbra, Inc.'s net margin of 7.22%. Penumbra, Inc.'s return on equity of 13.4% beat Merit Medical Systems, Inc.'s return on equity of 8.28%.

Penumbra, Inc. has a consensus price target of $306.79, signalling upside risk potential of 7.38%. On the other hand Merit Medical Systems, Inc. has an analysts' consensus of $103.00 which suggests that it could grow by 22.2%. Given that Merit Medical Systems, Inc. has higher upside potential than Penumbra, Inc., analysts believe Merit Medical Systems, Inc. is more attractive than Penumbra, Inc..

Penumbra, Inc. has a beta of 0.663, which suggesting that the stock is 33.676% less volatile than S&P 500. In comparison Merit Medical Systems, Inc. has a beta of 0.615, suggesting its less volatile than the S&P 500 by 38.504%.

Penumbra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra, Inc. pays -- of its earnings as a dividend. Merit Medical Systems, Inc. pays out -- of its earnings as a dividend.

Penumbra, Inc. quarterly revenues are $354.7M, which are smaller than Merit Medical Systems, Inc. quarterly revenues of $384.3M. Penumbra, Inc.'s net income of $45.9M is higher than Merit Medical Systems, Inc.'s net income of $27.8M. Notably, Penumbra, Inc.'s price-to-earnings ratio is 68.28x while Merit Medical Systems, Inc.'s PE ratio is 43.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra, Inc. is 8.39x versus 3.46x for Merit Medical Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of 12.93% compared to Penumbra, Inc.'s net margin of 7.29%. Penumbra, Inc.'s return on equity of 13.4% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

Penumbra, Inc. has a consensus price target of $306.79, signalling upside risk potential of 7.38%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 3.89%. Given that Penumbra, Inc. has higher upside potential than Phibro Animal Health Corp., analysts believe Penumbra, Inc. is more attractive than Phibro Animal Health Corp..

Penumbra, Inc. has a beta of 0.663, which suggesting that the stock is 33.676% less volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

Penumbra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.16% to investors and pays a quarterly dividend of $0.12 per share. Penumbra, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Penumbra, Inc. quarterly revenues are $354.7M, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. Penumbra, Inc.'s net income of $45.9M is higher than Phibro Animal Health Corp.'s net income of $26.5M. Notably, Penumbra, Inc.'s price-to-earnings ratio is 68.28x while Phibro Animal Health Corp.'s PE ratio is 24.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra, Inc. is 8.39x versus 1.21x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Universal Health Services, Inc. has a net margin of 12.93% compared to Penumbra, Inc.'s net margin of 8.43%. Penumbra, Inc.'s return on equity of 13.4% beat Universal Health Services, Inc.'s return on equity of 20.13%.

Penumbra, Inc. has a consensus price target of $306.79, signalling upside risk potential of 7.38%. On the other hand Universal Health Services, Inc. has an analysts' consensus of $249.94 which suggests that it could grow by 8.6%. Given that Universal Health Services, Inc. has higher upside potential than Penumbra, Inc., analysts believe Universal Health Services, Inc. is more attractive than Penumbra, Inc..

Penumbra, Inc. has a beta of 0.663, which suggesting that the stock is 33.676% less volatile than S&P 500. In comparison Universal Health Services, Inc. has a beta of 1.272, suggesting its more volatile than the S&P 500 by 27.185%.

Penumbra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Universal Health Services, Inc. offers a yield of 0.35% to investors and pays a quarterly dividend of $0.20 per share. Penumbra, Inc. pays -- of its earnings as a dividend. Universal Health Services, Inc. pays out 4.76% of its earnings as a dividend. Universal Health Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Penumbra, Inc. quarterly revenues are $354.7M, which are smaller than Universal Health Services, Inc. quarterly revenues of $4.5B. Penumbra, Inc.'s net income of $45.9M is lower than Universal Health Services, Inc.'s net income of $379.1M. Notably, Penumbra, Inc.'s price-to-earnings ratio is 68.28x while Universal Health Services, Inc.'s PE ratio is 10.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra, Inc. is 8.39x versus 0.89x for Universal Health Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.